Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT05347134
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
- NCT05347134 ↗
- Active, not recruiting
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Controlled, Open-label, Multi-center Phase III Clinical Trial of SKB264 for Injection Versus Investigator Selected Regimens in Patients With Unresectable Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Who Have Failed Second-line or Above Prior Standard of Care
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- SKB264
- Arms
- SKB264 · Active comparator
- Eribulin or Capecitabine or Gemcitabine or Vinorelbine · Active comparator
- Enrollment
- 254 (estimated)
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Start
- Jun 10, 2022
- Primary completion
- Nov 30, 2023
- Results posted
- No
- Registry record
- NCT05347134 · updated May 8, 2026
Publications
linked from the registry- Fan Y, Ouyang Q, Yin Y, Song L, Wang X, Li W, Li M, Yan X, Wang S, Sun T, Teng Y, Tang X, Tong Z, Sun Z, Ge J, Jin X, Diao Y, Liu G, Xu B. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study. Breast Cancer Res. 2026 Sep 28;28(1):163. doi: 10.1186/s13058-026-02339-z. PubMed 42806387
- Yin Y, Fan Y, Ouyang Q, Song L, Wang X, Li W, Li M, Yan X, Wang S, Sun T, Teng Y, Tang X, Tong Z, Sun Z, Ge J, Jin X, Diao Y, Liu G, Xu B. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2025 Jun;31(6):1969-1975. doi: 10.1038/s41591-025-03630-w. Epub 2025 Apr 11. PubMed 40217078